With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
SYK — frequently asked questions
Is Stryker Corporation overvalued?
In our latest published analysis dated 2026-10-22, SYK looks modestly undervalued. The price recorded at analysis is USD 298 versus our fair value of USD 313; the high endpoint is presented separately as potential value of USD 413. That implies roughly 5.2% upside to fair value at that date.
Our latest published report, analyzed 2026-10-22, gives SYK a fair value of USD 313 and a potential value of USD 413. The conclusion is triangulated across multiple valuation models and weighted by reliability for Stryker Corporation's archetype; it is a dated research output, not a live price.
Should I buy SYK now?
Our latest published rating for SYK, analyzed 2026-10-22, is Hold. Stryker Corporation looks modestly undervalued at the analysis-date price of USD 298 versus fair value of USD 313; potential value is USD 413. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for SYK?
The dedicated bear-case section in our report analyzed 2026-10-22 documents Stryker Corporation's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is SYK's rating?
Our latest published rating for SYK, analyzed 2026-10-22, is Hold, with a published moat assessment of 8.5/10 (Narrow). It reflects our fair value of USD 313, the potential value of USD 413, and the price recorded at analysis (USD 298).
Accelerated global Mako robotic penetration across inpatient hospitals and outpatient Ambulatory Surgery Centers, driving proprietary knee and hip implant pull-through and expanding international revenue beyond the current 24.3% non-U.S.
Main risk
A macroeconomic contraction or hospital budgetary austerity leading to deferred capital equipment commitments and delayed Mako placements.
Stryker Corporation (NYSE: SYK) carries a Hold rating with a fair value of $313.18, reflecting balanced risk-reward as strong procedural demand and robotic surgical leadership are counterbalanced by full valuation at $297.60 and transient operational overhead.4
Stryker Corporation has demonstrated operational resilience following first-quarter cyber and manufacturing disruptions, delivering healthy procedural demand across core reconstructive and endoscopy lines. Management has narrowed its full-year guidance corridor, projecting organic net sales growth between 8.3% and 9.3% and adjusted diluted earnings per share of $14.95 to $15.10. Expanding operating cash generation and disciplined capital allocation continue to reinforce the business model's free cash flow durability.5
While Stryker's competitive position in robotic surgery and hospital infrastructure remains entrenched, current market pricing reflects much of this operating recovery. Trading at $297.60, shares offer an implied return of +5.24% relative to the committee's $313.18 fair value midpoint. With valuation multiples elevated relative to medical device peers (such as BSX at 13.18x forward P/E and GEHC at 12.98x) and macroeconomic interest rates sustained at 5.15%, the committee maintains a Hold rating pending a wider margin of safety.2,3,4
Looking forward, execution will center on clearing acute Peripheral Vascular backorders by the end of Q3, converting elevated Mako robotic and smart bed backlogs into revenue, and managing a seamless executive transition to incoming CEO Spencer Stiles on January 1, 2027. Investors should maintain existing holdings while waiting for valuation pullbacks to add exposure.5
Robotic Orthopedic Moat and Sticky Consumable Pull-Through
Stryker's Mako system continues to set placement records across hospitals and ASCs, driving recurring, high-margin sales of proprietary knee and hip implants that solidify surgeon loyalty.5
As transient cyber remediation expenses and manufacturing absorption drag subside, operating leverage and efficiency initiatives are poised to drive multi-year adjusted operating margin expansion across both MedSurg and Orthopaedics.5
Hold. Stryker is a best-in-class medtech compounder with widening competitive moats in robotic surgery, but current market pricing leaves valuation balanced against fundamental intrinsic value.
Company overview
Stryker Corporation is a global medical technology company delivering innovative solutions across MedSurg and Neurotechnology as well as Orthopaedics. In FY2025, Stryker generated $25,116M in net sales, comprising $15,647M from MedSurg and Neurotechnology and $9,469M from Orthopaedics. Geographically, the United States accounted for $19,006M (75.7%) of net sales while international markets generated $6,110M (24.3%).
The company's diverse commercial portfolio includes joint replacement implants, surgical power tools, advanced endoscopy systems, neurosurgical devices, patient handling equipment, and connected clinical software, serving healthcare providers worldwide. Stryker announced that executive Spencer Stiles will succeed Kevin Lobo as Chief Executive Officer, with Lobo transitioning to Executive Chair of the Board.
Under a combined macroeconomic slowdown and hospital capex freeze, capital equipment commitments are deferred and hospital procedural volumes soften. In this stress scenario, organic net sales growth slows below 4.0%, manufacturing fixed costs and elevated IT security overhead depress operating margins below 16.5%, and valuation multiples compress toward the peer medtech range of 13.0x-14.0x forward earnings, severely impairing intrinsic economic value.
Stryker Corporation possesses a Narrow economic moat founded on high customer switching costs, extensive operating room distribution scale, and an integrated clinical technology portfolio. The company's crown jewel is its Mako robotic-assisted orthopedic surgery system, which has established an industry-leading installed base that drives recurring sales of proprietary implants across total knee, partial knee, and total hip procedures. Hospital systems and surgeons invest heavily in robotic capital, software configuration, and surgical technique training, creating friction that disincentivizes switching to competing robotic platforms.
Complementing its orthopedic leadership, Stryker's MedSurg and Neurotechnology businesses command dominant market shares in surgical instruments, endoscopy, emergency care, and hospital infrastructure. By bundling capital equipment such as ProCuity smart beds with clinical workflow software from Vocera and Care.ai, Stryker embeds itself deeply into hospital enterprise procurement workflows, securing recurring consumable demand and reinforcing pricing stability even amidst broader healthcare budgeting pressures.
Stryker generates returns well in excess of its cost of capital. In FY2025, operating profit of $4,889M on $25,116M revenue and an invested capital base of $38,279M supported a return on invested capital of 11.45%. This exceeds the company's weighted average cost of capital of 8.21% and moderate of 8.64%, confirming persistent creation.
The highlighted cell is Fair value when every assumption sits at its base level ($313.18). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $3.6B after modeled reinvestment of $895.4M, with terminal value at 79.7% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
EPS annual compound growth of 12.5% through explicit forecast horizon.
§7 Earnings decision tree
Beat
Upgrade the rating; Re-evaluate capital allocation weighting, assess ASC order fulfillment acceleration, and review whether manufacturing capacity can absorb higher multi-year backlog without cost inflation.
Trigger: Organic net sales growth > 9.3% YoY and full-year adjusted EPS > $15.10 with operating margins expanding above 20.5%.5
Delivering results above the high end of organic sales guidance alongside robust margin recovery would prove that Mako adoption and operating leverage are running ahead of house expectations, justifying a positive rating revision.
In-line
Maintain Hold; Maintain current portfolio weighting, verify conversion of elevated capital equipment backlog into shipped , and check Q3 Peripheral Vascular backorder clearance milestones.
Industry capital expenditures track at 4.5% of revenue with a capex-to-depreciation ratio of 0.8x, indicating disciplined replacement capex rather than aggressive capacity overexpansion. Stryker's own FY2025 capex of $761M on $25,116M revenue (3.03%) further demonstrates restrained capital intensity. Because adapter data does not supply comprehensive equipment lead times or utilization metrics, the industry cycle view is demand-led and evidence-limited.7
Bull cycle
Robust hospital capex budgets, accelerating migration of joint reconstructions to ASCs, record robotic conversions, and steady procedure volume expansion drive double-digit EPS growth and multiple expansion across large-cap medtech.
§11 Position management
Sizing
3-4%
A Hold rating reflects balanced risk-reward with shares trading at $297.60 (as of 2026-10-21) relative to Fair value of $313.18. While Stryker is a high-conviction compounder, full valuation caps incremental position sizing.
Risk
Control portfolio exposure through strict position sizing caps, rebalance opportunistically as valuation reaches extreme bands, and maintain diversification across less capital-sensitive healthcare segments.
Entry tranches
Level
Action
Why
Discount to Fair value tranche
Deploy initial incremental capital to establish an initial portfolio tranche.
§12 Investor perspectives
Core Quality Compounder
Hold
Stryker offers exceptional structural advantages, an expanding robotic surgery ecosystem, and robust free cash flow conversion, but shares at $297.60 trade near fair value ($313.18), warranting a patient stance for better entry points.4
Value Investor
Hold
With shares trading at $297.60 (as of 2026-10-21) offering an upside of 5.2% to Fair value of $313.18, valuation does not offer an adequate margin of safety relative to prevailing risk-free interest rates.2
Tactical / Momentum Investor
Hold
Post-earnings consensus estimate revisions are flat and ranges are tightly bound, suggesting limited near-term multiple re-rating catalysts until supply chain normalization and Mako order conversion deliver upside surprises.
§14 Final recommendation
Action
Hold
Stryker Corporation is an elite medical technology compounder with a Narrow economic moat established across robotic orthopedic surgery and hospital infrastructure. However, with shares trading at $297.60 relative to our fair value midpoint of $313.18 (+5.24% implied return), market pricing adequately reflects near-term operational recovery, justifying a Hold rating.4
Investors should retain existing allocations, monitor execution on elevated capital equipment order backlogs and Q3 Peripheral Vascular supply resolution, and await wider valuation discounts before committing fresh capital.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-22 · Published 2026-10-22 · Provider-adjusted · cited for 4 figuresCited in Scenarios, Earnings decision tree
Hospital budgetary tightening leads to deferred capital equipment commitments, prolonged supply chain backorders constrain vascular sales, and persistent IT remediation overhead limits operating leverage, restricting EPS compounding to low-single digits.
Ways this thesis can break
Hospital Capital Equipment Freeze and Placement Deferrals
Hospital budgetary austerity or recessionary capex cuts delay Mako robot purchases and bed replacements, which currently drive elevated backlog. If organic growth slows below 4.0% (well below guided 8.3%-9.3%), fixed manufacturing costs erode operating leverage.5
FV impact
-3.8%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 12 months
Persistent Cyber Remediation Overhead and Absorption Drag
Continued costs from lost manufacturing absorption, elevated IT cybersecurity spending, and unabsorbed overhead as described by management depress operating margins below 16.5%, reverting toward 2024 levels (16.33%) and industry benchmark (15.5%).5
FV impact
-1.5%
Operating margin 3 points lower throughout
Trigger
Within 18 months
Macro Valuation Compression and Peer Multiple Convergence
Persistent higher interest rates (risk-free rate 5.15%) compress valuation multiples toward peer BSX forward P/E of 13.18x and GEHC forward P/E of 12.98x, derating Stryker from its terminal 18.0x assumption to 14.0x.2,3
FV impact
-6.1%
Terminal multiple 20% lower
Trigger
Within 12 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
01
Organic Net Sales Growth Rate
Deceleration below 4.0% indicates hospital capital budget freezes and surgical procedure deferrals, invalidating top-line compounding.
Current:9.0% YoY in Q2 2026 (full-year guided 8.3%-9.3%)
Prolonged negative growth past Q4 2026 indicates permanent customer defection and market share loss to competitors rather than transient supply friction.
Current:-6.7% YoY in Q2 2026
Alert ifNegative YoY organic growth persisting past Q4 2026
05
Hospital Capital Equipment Order Conversion and Backlog Delivery
Order cancellations or lengthening conversion cycles signal hospital capital spending retrenchment, impairing high-margin capital equipment revenue.
Current:Elevated backlog with record Mako sales in Q2 2026
Alert ifNet backlog contraction or order cancellations exceeding 5% YoY
01High Customer Switching Costs in Robotic Surgery Ecosystem — Stryker's Mako robotic-arm platform deeply embeds proprietary Triathlon knee and hip implants into hospital surgical workflows and orthopedic surgeon practice, generating exceptionally high switching costs and reliable high-margin consumable implant pull-through.Wide
02Dominant Operating Room Distribution Scale and Portfolio Breadth — With FY2025 revenue of $15,647M in MedSurg and Neurotechnology and $9,469M in Orthopaedics, Stryker possesses an expansive commercial sales and service infrastructure that creates high barriers to entry and strong cross-selling leverage across hospital procurement departments.Wide
03Software Integration and Connected Healthcare Ecosystem — Stryker's integrated hospital infrastructure—combining ProCuity connected hospital beds, Vocera clinical communication systems, and Care.ai SmartCare digital workflows—creates a sticky, interconnected clinical IT ecosystem embedded across healthcare networks.Moderate
Hospital capital budget freezes and placement delays for major capital equipment
medium
12-18 months
Offering flexible acquisition models, expanding penetration into high-growth Ambulatory Surgery Centers, and relying on recurring procedural implant demand that insulates against purely capital freezes.5
Supply chain bottlenecks and operational disruptions in specialized product lines
medium
6-12 months
Adding manufacturing shifts, stabilizing sales force integration, and resolving component bottlenecks to restore delivery timelines by end of Q3.5
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Adjusted operating margin expands beyond 21.2% ahead of schedule.
Rapid ASC robotic placement acceleration and sustained procedure volume expansion.5
Accelerated hospital capital equipment spending, record Mako robotic placements in hospital and ASC settings, and rapid clearance of Peripheral Vascular backorders drive double-digit earnings compounding and accelerated operating margin expansion ahead of house expectations.5
FY2026 revenue of $27.17B and adjusted EPS of $14.95.1
FY2027 revenue of $29.49B and adjusted EPS of $16.66.1
Operating margin expands from 19.5% in FY2026 to 21.2% in FY2030.
Terminal exit P/E multiple of 18.0x and perpetual growth rate of 3.0%.
Stryker executes within its guided organic sales growth corridors, transitioning to steady high-single-digit revenue expansion through FY2030 supported by resilient reconstructive procedure volumes and steady operating margin progression.5
Trigger: Organic net sales growth between 8.3% and 9.3% YoY and full-year adjusted EPS between $14.95 and $15.10.5
Financial performance within guided corridors affirms the baseline recovery thesis, but current market valuation fairly balances operational compounding against macroeconomic risks.
Miss
Downgrade the rating; Trim position size toward conservative allocation limits, review hospital capex budget health, and re-underwrite terminal valuation multiples.
Trigger: Organic net sales growth < 8.3% YoY or full-year adjusted EPS < $14.95 with operating margins falling below 19.0%.5
Missing guided ranges would indicate that hospital capex deferrals are materializing, competitive pressures are restricting placements, or operational and cyber remediation costs are lingering, warranting a rating downgrade.
Stryker exhibits high earnings quality supported by disciplined cash conversion, transparent non-GAAP reporting reconciliations, and healthy working capital management. Operating cash flow tracks net income closely, underscoring strong cash conversion across hospital capital equipment and orthopaedic implant deliveries. The spread between GAAP and adjusted diluted earnings per share primarily reflects routine amortization of purchased intangible assets alongside transient structural optimization and cyber recovery charges, rather than aggressive operational accounting adjustments.
Estimate momentum
Consensus analyst revisions following the Q2 2026 earnings release have remained flat across both revenue and EPS curves. Consensus FY2026 diluted EPS settled at $14.95 (within management's narrowed $14.95-$15.10 guidance range) and FY2027 diluted EPS held steady at $16.66. Consensus revenue estimates for FY2026 of $27.17B and FY2027 of $29.49B align with house baseline expectations.1,5
Metrics to watch into the print
01
Metric:
Full-Year Organic Net Sales Growth Corridor
CurrentDelivered 9.0% organic sales growth in Q2 2026; full-year guidance narrowed to 8.3%-9.3%.
Why it matters
Validates whether core procedure volumes and hospital capital spending support management's target to grow at the upper tier of medical technology.
CurrentAdjusted operating margin expanded year-over-year in the second quarter, demonstrating sequential recovery as manufacturing absorption normalizes.
Why it matters
Confirms that manufacturing fixed-cost absorption and efficiency programs are offsetting residual cyber remediation expenses.5
03
Metric:
Peripheral Vascular Backorder Normalization
CurrentU.S. organic sales declined 6.7% in Q2 2026; management expects backorders to reach manageable levels by end of Q3.
Why it matters
Tests the speed of supply chain resolution and verifies customer retention following acute manufacturing disruptions.5
04
Metric:
Mako Robotic Placements and ASC Adoption
CurrentAchieved record monthly Mako sales in Q2 2026 with an elevated placement backlog.
Why it matters
Directly drives proprietary implant pull-through in knees and hips across outpatient surgical facilities.5
05
Metric:
Executive Leadership Succession Execution
CurrentSpencer Stiles appointed Chief Executive Officer effective in early 2027, with Kevin Lobo transitioning to Executive Chair.
Why it matters
Maintains continuity of Stryker's acquisition playbook, organizational culture, and operating model.
Stryker demonstrates high cash flow quality characterized by disciplined capital expenditure and strong conversion. In FY2025, operating cash flow reached $5,044M, which after capital expenditures of $761M yielded free cash flow of $4,283M (an 84.9% free cash flow conversion of operating cash flow). In the first half of 2026, operating cash flow increased 35.3% YoY to $1,842M, supported by working capital improvements following initial cyber incident disruptions. Capex remained modest at $368M in 6M 2026, confirming the asset-light nature of Stryker's ongoing operations.6,7
Stryker maintains a disciplined, shareholder-friendly capital allocation strategy focused on programmatic tuck-in acquisitions, dividend growth, and selective share repurchases. Under CEO Lobo, the company completed over 60 acquisitions, including transformative transactions such as Mako, Wright Medical, Vocera, and Inari. In the first six months of 2026, Stryker invested $459M in acquisitions, paid $674M in dividends, and executed $750M in net debt payments. Total debt of $15,446M against a market capitalization of $114,151M reflects a modest 11.92% debt weight, preserving ample borrowing headroom, while approximately $1 billion in authorized repurchase capacity remains available for opportunistic share buybacks.
Stryker's ROIC of 11.45% delivers a positive economic spread of +324 bps above its 8.21% WACC. Operating margin progression from 19.47% in FY2025 toward 21.2% by FY2030 will expand ROIC further as post-incident manufacturing absorption normalizes.
ROIC of 11.45% exceeds computed WACC of 8.21% by 3.24 percentage points.
Exceptional Free Cash Flow Conversion Powered by Low Capital Intensity
Restrained capital intensity generates abundant surplus cash flow, enabling continuous tuck-in M&A and dividend increases without stretching the balance sheet.
Operating margins rebounded from 16.33% in FY2024 to 19.47% in FY2025, and adjusted operating margin expanded 170 bps YoY to 27.4% in Q2 2026.
Fixed-cost recovery from manufacturing shutdowns and tapering cyber IT overhead create a reliable runway to reach 21.2% operating margins by FY2030.
Diversified Business Mix Insulates Enterprise Growth
In Q2 2026, MedSurg and Neurotechnology delivered 9.7% reported growth ($3,625M) while Orthopaedics delivered 9.1% reported growth ($2,964M).
Broad procedural and equipment diversification insulates enterprise revenue from isolated segment disruptions, such as the temporary -6.7% decline in U.S. Peripheral Vascular sales.
Stryker Corporation (SYK) trades at 16.5x forward earnings against a peer median of 15.6x. Its EV/EBITDA of 17.1x compares with a peer median of 13.8x. The comparison uses 4 peers: Boston Scientific Corporation, GE HealthCare Technologies Inc., Edwards Lifesciences Corporation and STERIS plc, as of 2026-10-21 to 2026-10-22.
Bear cycle
Hospital financial austerity and capex freezes delay robotic placements and bed replacements, while persistent supply chain bottlenecks and elevated interest rates depress industry valuation multiples toward 13x-14x forward earnings.
Secular trends
Trend
Impact
Note
Aging Demographics and Rising Orthopedic Procedure Volumes
positive
Aging global demographics and longer active lifespans drive steady procedural volume growth in knee, hip, and trauma joint replacements, underpinning sustained multi-year demand.
Migration of Joint Reconstruction to Ambulatory Surgery Centers (ASCs)
positive
Surgical procedure migration to outpatient Ambulatory Surgery Centers creates fresh demand for robotic-assisted surgery systems tailored for ASC economics.
Hospital Workflow Automation and Healthcare IT Connectivity
positive
Hospitals increasingly adopt connected bed systems (ProCuity) and clinical communication platforms (Vocera, Care.ai) to enhance nurse efficiency, patient safety, and workflow automation.
Regulatory Compliance and Component Supply Chain Constraints
neutral
Complex regulatory requirements including European Medical Device Regulation (EU MDR) and specialized medical supply chain vulnerabilities introduce localized backorders and compliance friction.
Positioning
Stryker commands leading global positions in Orthopaedics ($9,469M FY2025 revenue) and MedSurg and Neurotechnology ($15,647M FY2025 revenue). Its dominant Mako robotic surgery footprint, comprehensive operating room equipment catalog, and connected software platforms position the company to outpace broader industry procedural growth and gain market share from fragmented competitors.8
Represents a >10% discount to our $313.18 fair value midpoint, providing an attractive risk-adjusted margin of safety.
Deep valuation compression tranche
Scale up allocation toward target portfolio weighting.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Discounted forecast-period cash flows ($43.86) plus discounted terminal value ($172) minus signed net debt per current share ($31.96) equals the $184 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
